Lückmann Michael, Holst Birgitte, Schwartz Thue W, Frimurer Thomas M
M Lückmann, B Holst, TW Schwartz, TM Frimurer, Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen. Denmark.
TM Frimurer, Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen. Denmark.
Mol Inform. 2016 Jan;35(1):19-24. doi: 10.1002/minf.201500080. Epub 2015 Sep 16.
The neurotensin receptor 1 (NTSR1) belongs to the family of 7TM, G protein-coupled receptors, and is activated by the 13-amino-acid peptide neurotensin (NTS) that has been shown to play important roles in neurological disorders and the promotion of cancer cells. Recently, a high-resolution x-ray crystal structure of NTSR1 in complex with NTS8-13 has been determined, providing novel insights into peptide ligand recognition by 7TM receptors. SR48692, a potent and selective small molecule antagonist has previously been used extensively as a tool compound to study NTSR1 receptor signaling properties. To investigate the binding mode of SR48692 and other small molecule compounds to NTSR1, we applied an Automated Ligand-guided Backbone Ensemble Receptor Optimization protocol (ALiBERO), taking receptor flexibility and ligand knowledge into account. Structurally overlapping binding poses for SR48692 and NTS8-13 were observed, despite their distinct chemical nature and inverse pharmacological profiles. The optimized models showed significantly improved ligand recognition in a large-scale virtual screening assessment compared to the crystal structure. Our models provide new insights into small molecule ligand binding to NTSR1 and could facilitate the structure-based design of non-peptide ligands for the evaluation of the pharmacological potential of NTSR1 in neurological disorders and cancer.
神经降压素受体1(NTSR1)属于7次跨膜G蛋白偶联受体家族,由13个氨基酸组成的神经降压素(NTS)肽激活,该肽已被证明在神经疾病和促进癌细胞生长中起重要作用。最近,已确定了与NTS8-13复合的NTSR1的高分辨率x射线晶体结构,为7次跨膜受体识别肽配体提供了新的见解。SR48692是一种强效且选择性的小分子拮抗剂,以前曾广泛用作研究NTSR1受体信号特性的工具化合物。为了研究SR48692和其他小分子化合物与NTSR1的结合模式,我们应用了一种自动配体引导的主链整体受体优化方案(ALiBERO),同时考虑了受体的灵活性和配体知识。尽管SR48692和NTS8-13具有不同的化学性质和相反的药理特性,但观察到它们在结构上重叠的结合姿态。与晶体结构相比,优化后的模型在大规模虚拟筛选评估中显示出显著改善的配体识别能力。我们的模型为小分子配体与NTSR1的结合提供了新的见解,并有助于基于结构设计非肽配体,以评估NTSR1在神经疾病和癌症中的药理潜力。